Medical
Technology
Pharmaceutical

Antares Pharma

$3.08
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.04 (-1.28%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Antares Pharma and other stocks, options, ETFs, and crypto commission-free!

About

Antares Pharma, Inc. engages in the development and commercialization of self-administered parenteral pharmaceutical products and technologies. Its proprietary products include XYOSTED (testosterone enanthate) injection, OTREXUP (methotrexate) injection for subcutaneous use, and Sumatriptan Injection. Read More The company was founded in February 1979 and is headquartered in Ewing, NJ.

Employees
165
Headquarters
Ewing, New Jersey
Founded
1979
Market Cap
498.33M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.17M
High Today
$3.14
Low Today
$3.03
Open Price
$3.11
Volume
464.63K
52 Week High
$3.96
52 Week Low
$1.99

Collections

Medical
Technology
Pharmaceutical
Health
US
North America

News

MarketBeatMar 17

Stock Price, News, & Analysis for Antares Pharma

Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Its in...

14
Simply Wall StMar 15

Should You Worry About Antares Pharma, Inc.’s (NASDAQ:ATRS) CEO Salary Level?

Bob Apple became the CEO of Antares Pharma, Inc. (NASDAQ:ATRS) in 2016. First, this article will compare CEO compensation with compensation at similar sized companies. After that, we will consider the growth in the business. Third, we’ll reflect on the total return to shareholders over three years, as a second measure of business performance. This process should give us an idea about how appropriately the CEO is paid. Check out our latest analysis for Antares Pharma How Does Bob Apple’s Compensation Compa...

205
Guru FocusMar 12

Antares Pharma Inc (ATRS) Files 10-K for the Fiscal Year Ended on December 31, 2018

Antares Pharma Inc (NASDAQ:ATRS) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Antares Pharma Inc is a specialty pharmaceutical company.

184

Earnings

-$0.04
-$0.01
$0.01
$0.04
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 7, Pre-Market

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.